TuHURA Biosciences, Inc. (HURA)
NASDAQ: HURA · Real-Time Price · USD
2.810
-0.110 (-3.77%)
Apr 20, 2026, 10:12 AM EDT - Market open
TuHURA Biosciences Employees
TuHURA Biosciences had 22 employees as of December 31, 2025. The number of employees increased by 3 or 15.79% compared to the previous year.
Employees
22
Change (1Y)
3
Growth (1Y)
15.79%
Revenue / Employee
n/a
Profits / Employee
-$1,366,379
Market Cap
178.66M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 22 | 3 | 15.79% |
| Dec 31, 2024 | 19 | 18 | 1,800.00% |
| Dec 31, 2023 | 1 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Replimune Group | 479 |
| Karyopharm Therapeutics | 228 |
| Protalix BioTherapeutics | 226 |
| Heron Therapeutics | 128 |
| Agenus | 81 |
| Cartesian Therapeutics | 75 |
| Corbus Pharmaceuticals Holdings | 36 |
| Whitehawk Therapeutics | 23 |
HURA News
- 13 days ago - TuHURA Biosciences Appoints Amanda Garofalo, MSHS, as Senior Vice President of Clinical Operations - PRNewsWire
- 19 days ago - TuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update - PRNewsWire
- 4 weeks ago - Craig Tendler, M.D., JNJ's Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience's VISTA Program in AML and other Blood Related Cancers - PRNewsWire
- 7 weeks ago - TuHURA Biosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement - PRNewsWire
- 7 weeks ago - TuHURA Biosciences Announces Participation in Upcoming Investor Conferences - PRNewsWire
- 2 months ago - TuHURA Files Investigational New Drug Application for TBS-2025 in the Treatment of Blood-Related Cancers - PRNewsWire
- 2 months ago - TuHURA Biosciences to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - PRNewsWire
- 2 months ago - TuHURA Biosciences received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB to Stage IV Cutaneous Melanoma - PRNewsWire